1. Home
  2. News Archive

More News

Santen and Kyorin to Jointly Market Eyelid Cream for Allergic Conjunctivitis in Japan
Santen and Kyorin to Jointly Market Eyelid Cream for Allergic Conjunctivitis in Japan

Japanese pharmaceutical companies Santen and Kyorin announced July 13 that they would jointly market Santen’s Alesion long-acting eyelid cream (epinastine hydrochloride 0.5%) for allergic conjuncti...

Atsena’s Gene Therapy Candidates for XLRS, LCA1 Gain EMA Orphan Designation
Atsena’s Gene Therapy Candidates for XLRS, LCA1 Gain EMA Orphan Designation

Atsena Therapeutics announced July 23 that the European Medicines Agency (EMA) had granted orphan designation to its two clinical-stage gene therapy candidates: ATSN-101 for Leber congenital amauro...

CMS Proposes Cuts to Physician Fees for 2027; Simple Cataract Surgery Would Pay $462 or $444
CMS Proposes Cuts to Physician Fees for 2027; Simple Cataract Surgery Would Pay $462 or $444

The Centers for Medicare and Medicaid Services (CMS) on July 14 published its proposed Physician Fee Schedule (PFS) for 2027. Similar to the 2026 schedule, one of two conversion factors will be use...

IPG Photonics to Acquire Lumibird Medical for €300 Million
IPG Photonics to Acquire Lumibird Medical for €300 Million

IPG Photonics has entered into a binding offer to acquire Lumibird Medical for €300 million (US $342.3 million), both companies announced July 16. A contingent earnout consideration of up to an add...

Kalshi Offers Betting on Drug Development Timelines and Results
Kalshi Offers Betting on Drug Development Timelines and Results

Prediction market Kalshi began on July 16 offering betting on a range of drug development milestones, ranging from clinical trial outcomes and timelines for submissions to US FDA decisions. The New...

WOC 2026 Explores How AI Can Expand Access to Eye Care
WOC 2026 Explores How AI Can Expand Access to Eye Care

Artificial intelligence is quickly evolving from a diagnostic tool into a comprehensive clinical assistant with the potential to expand access to eye care worldwide, as emphasized at the 2026 World...

Atsena Will Advance ATSN-401 Gene Therapy Candidate for Stargardt
Atsena Will Advance ATSN-401 Gene Therapy Candidate for Stargardt

Atsena Therapeutics announced July 9 that it would advance ATSN-401, a gene therapy candidate for Stargardt disease. Stargardt is an inherited neurodegenerative disease that leads to macular degene...

Ocugen Secures Deal with Roots Pharmaceutical for OCU400 in MENA Region
Ocugen Secures Deal with Roots Pharmaceutical for OCU400 in MENA Region

Ocugen announced July 13 that it had signed a binding term sheet for a license agreement with Kuwait’s Roots Pharmaceutical for exclusive rights to OCU400, Ocugen’s subretinal modifier gene therapy...

Santen Gains Philippines Marketing Approval for Ryjusea (Atropine) for Myopia
Santen Gains Philippines Marketing Approval for Ryjusea (Atropine) for Myopia

Japan’s Santen Pharmaceutical announced June 26 that it had gained marketing approval in the Philippines for preservative-free Ryjusea low-dose atropine drops to slow the progression of pediatric m...

US FDA Grants RMAT Status to Emmecell’s Corneal Cell Therapy Candidate
US FDA Grants RMAT Status to Emmecell’s Corneal Cell Therapy Candidate

Emmecell announced July 7 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to EO2002, the company’s corneal endothelial cell therapy candidate. The RMAT designa...

NovaBridge Biosciences Appoints Srishti Gupta, MD, as Chief Executive Officer
NovaBridge Biosciences Appoints Srishti Gupta, MD, as Chief Executive Officer

NovaBridge Biosciences announced June 29 that it had appointed Srishti Gupta, MD, as chief executive officer and a member of the company’s board of directors. The company said that Xi-Yong (Sean) F...

Exonate Appoints Olav Hellebø as Chief Executive Officer
Exonate Appoints Olav Hellebø as Chief Executive Officer

British company Exonate announced June 30 that it had appointed Olav Hellebø as chief executive officer. Exonate is developing EXN407, an eye drop candidate entering Phase IIb study for diabetic ey...

China’s Myopia Prevention Success Could Reshape a Still-Expanding Market
China’s Myopia Prevention Success Could Reshape a Still-Expanding Market

Recent data presented at the 2026 World Ophthalmology Congress demonstrate that China’s myopia reduction efforts are working. Myopia reduction initiatives by Chinese government agencies call for co...

Octane Analyzes How AI and Practice Workflow are Driving Tech Innovation
Octane Analyzes How AI and Practice Workflow are Driving Tech Innovation

The 2026 Octane Ophthalmology Tech Forum focused on how advances in artificial intelligence and physician workflow are influencing the develop-ment and commercialization of new ophthalmic technolog...

Robotic Cataract Surgery Can Serve as Catalyst for Premium Growth
Robotic Cataract Surgery Can Serve as Catalyst for Premium Growth

Robotic cataract surgery remains a hot topic in ophthalmology, fueled by recent first-in-human procedures and a growing pipeline of robotic platforms. A digitally guided, highly precise surgical sy...

RxSight to Collaborate with Alcon on PC-IOLs Under New CEO
RxSight to Collaborate with Alcon on PC-IOLs Under New CEO

RxSight has made two significant moves following disappointing sales results in Q2-2026. The Aliso Viejo, California, company announced July 6 that it would collaborate with Alcon to develop adjust...

LensCrafters Adds Refractive and Cataract Surgery Options to New Center
LensCrafters Adds Refractive and Cataract Surgery Options to New Center

LensCrafters, part of French company EssilorLuxottica, announced June 30 that it was launching the first LensCrafters Vision & Eye Health Center, adding surgical procedures and advanced diagnostics...

Select US FDA Approvals and Clearances in June 2026
Select US FDA Approvals and Clearances in June 2026

The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in June 2026, according to the agency’s database. Topcon received clearance for the Harmony Refer...

PDUFA Dates for Ophthalmic Drug Candidates, July 2026
PDUFA Dates for Ophthalmic Drug Candidates, July 2026

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

US FDA Approves First Challenger to Tepezza: Lumvoa from Viridian
US FDA Approves First Challenger to Tepezza: Lumvoa from Viridian

Viridian Therapeutics announced June 29 that the US FDA had approved Lumvoa (veligrotug-vvze), an infusion treatment for thyroid eye disease (TED). The company said Lumvoa would launch immediately....

MACs Propose Limiting Coverage for iDose TR in Glaucoma Patients
MACs Propose Limiting Coverage for iDose TR in Glaucoma Patients

Five Medicare administrative contractors (MACs) in the US are proposing to limit coverage for procedures implanting the Glaukos iDose TR in patients with glaucoma. The iDose TR is a drug-eluting in...

US FDA Advisory Panel Will Review Sydnexis’ NDA for SYD-101 in Myopia
US FDA Advisory Panel Will Review Sydnexis’ NDA for SYD-101 in Myopia

Sydnexis announced July 13 that the US FDA would convene an advisory committee meeting to discuss SYD-101, the company’s low-dose atropine candidate for pediatric progressive myopia. The date for t...

Gene Therapy Research Targets Root Cause of Open-Angle Glaucoma
Gene Therapy Research Targets Root Cause of Open-Angle Glaucoma

New research presented at the 2026 World Ophthalmology Congress suggests that gene therapy may offer a way to treat the underlying cause of primary open-angle glaucoma rather than lowering intraocu...

Lenz Launches Telehealth Prescribing Option for Vizz Presbyopia Drops
Lenz Launches Telehealth Prescribing Option for Vizz Presbyopia Drops

Lenz Therapeutics announced July 6 that it was making its presbyopia drop, Vizz, available online through a telehealth platform at getvizz.com. Lenz said an independent network of licensed eye care...

Ollin Leads Latest Fundraising with $330 Million in Series B Financing
Ollin Leads Latest Fundraising with $330 Million in Series B Financing

Ollin Biosciences led recent ophthalmic fundraising efforts with $330 million in a Series B round to advance its candidates for retinal and thyroid eye disease. Financing announced in the past four...

Vermont Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy, Crosslinking
Vermont Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy, Crosslinking

Vermont has become the 17th US state to pass a law expanding optometrists’ scope of practice to include in-office laser procedures. Senate Bill 64, signed into law by Gov. Phil Scott on June 18, gr...

Harrow Relaunches Samsung Bioepis’ Biosimilar Byooviz in the US
Harrow Relaunches Samsung Bioepis’ Biosimilar Byooviz in the US

Harrow announced July 1 that it had relaunched Byooviz, a Lucentis biosimilar, in the US. The Nashville, Tennessee, company secured US rights to Byooviz (ranibizumab-nuna) and another ophthalmic bi...

Emerging Companies Pursuing Ophthalmic Indications, July 2026
Emerging Companies Pursuing Ophthalmic Indications, July 2026

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Weekly Surgeon Poll, US Ophthalmologists and Optometrists, July 2026
Weekly Surgeon Poll, US Ophthalmologists and Optometrists, July 2026

Clinical Trial Updates for Ophthalmic Candidates, July 2026
Clinical Trial Updates for Ophthalmic Candidates, July 2026

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

July 2026 Ophthalmic News Briefs
July 2026 Ophthalmic News Briefs

Johnson & Johnson reported June 15 that it would invest more than $1 billion in its Jacksonville, Florida, operations to scale US-based manufacturing, packaging, and distribution for its Acuvue con...

US FDA Advisory Panel Will Review Sydnexis’ NDA for SYD-101 in Myopia
US FDA Advisory Panel Will Review Sydnexis’ NDA for SYD-101 in Myopia

Sydnexis announced July 13 that the US FDA would convene an advisory committee meeting to discuss SYD-101, the company’s low-dose atropine candidate for pediatric progressive myopia. The date for t...

US FDA Recalls 2.5 Million Bottles of Prednisolone Acetate Eye Drops
US FDA Recalls 2.5 Million Bottles of Prednisolone Acetate Eye Drops

The US FDA has issued a Class II recall of more than 2.5 million bottles of prednisolone acetate 1% eye drops manufactured by Lupin Limited, citing the possibility of foreign particulate contaminat...

Bausch + Lomb Drops Glaucoma Neuroprotection Program after Phase II Failure
Bausch + Lomb Drops Glaucoma Neuroprotection Program after Phase II Failure

Bausch + Lomb announced July 10 that it would discontinue development of a neuroprotective eye drop candidate for glaucoma, citing Phase II results in which BL1107, a prodrug of brimonidine tartrat...

RxSight Appoints Aziz Mottiwala as President, CEO
RxSight Appoints Aziz Mottiwala as President, CEO

RxSight reported July 15 that it had appointedAziz Mottiwala as president and chief executive officer, effective July 20. Mottiwala succeeds Ron Kurtz, MD, who will continue to serve as chief medic...

J&J Vision Generates Q2-2026 Surgical Revenue of $426 Million
J&J Vision Generates Q2-2026 Surgical Revenue of $426 Million

J&J Vision’s Q2-2026 global surgical revenue totaled $426 million, a 5.6 percent increase over $403 million in Q2-2025, parent Johnson & Johnson, of New Brunswick, New Jersey, reported July 15. Q2-...

Tarsus Acquires iRenix, Developer of Pre-procedure Ocular Antiseptic Candidate
Tarsus Acquires iRenix, Developer of Pre-procedure Ocular Antiseptic Candidate

Tarsus Pharmaceuticals announced July 8 that it had acquired iRenix Medical, of Palo Alto, California, developer of IRX-101, an investigational ocular antiseptic. Tarsus said it would pay approxima...

Tenpoint Submits UK Marketing Application for Yuvezzi Presbyopia Drops
Tenpoint Submits UK Marketing Application for Yuvezzi Presbyopia Drops

Tenpoint Therapeutics reported July 13 that it had submitted a marketing authorization application to the UK’s Medicines and Healthcare Products Regulatory Agency for Yuvezzi (carbachol and brimoni...

Hengrui’s Cyclosporine Eye Drop Formulation for Dry Eye Gains Approval in China
Hengrui’s Cyclosporine Eye Drop Formulation for Dry Eye Gains Approval in China

China’s Hengrui Pharmaceuticals and Germany’s Novaliq announced June 30 that China’s National Medical Products Administration had approved Heng Yi (0.1% cyclosporine ophthalmic solution) for dry ey...

Vivani’s Cortigent to Merge with Nasdaq-Listed ClearOne
Vivani’s Cortigent to Merge with Nasdaq-Listed ClearOne 

Vivani Medical, of Alameda, California, reported July 2 that its Cortigent subsidiary— which is developing the Orion visual cortex implant—would merge with Nasdaq-listed ClearOne to form Cortigent ...

Alcon and RxSight to Collaborate on Developing Adjustable PC-IOLs
Alcon and RxSight to Collaborate on Developing Adjustable PC-IOLs

Alcon and RxSight willjointly develop adjustable presbyopia-correcting intraocular lenses (PC-IOLs) under a new nonexclusive agreement, the companies announced July 6. The collaboration aims to com...

Harrow Relaunches Lucentis Biosimilar Byooviz in the US
Harrow Relaunches Lucentis Biosimilar Byooviz in the US

Harrow announced July 1 that it had relaunched Byooviz (ranibizumab-nuna), a Lucentis biosimilar, in the US. The Nashville, Tennessee, company secured US rights to Byooviz and another ophthalmic bi...

LensCrafters Adds Refractive and Cataract Surgery Options to New Center
LensCrafters Adds Refractive and Cataract Surgery Options to New Center

LensCrafters, part of French company EssilorLuxottica, announced June 30 that it was launching the first LensCrafters Vision & Eye Health Center, addingsurgical procedures and advanced diagnostics ...

US FDA Accepts sBLA for Genentech Subcutaneous TED Candidate, Grants Priority Review
US FDA Accepts sBLA for Genentech Subcutaneous TED Candidate, Grants Priority Review

Genentech announced June 30 that the US FDA had accepted its supplemental biologics license application (sBLA) for subcutaneous Enspryng (satralizumab) in thyroid eye disease (TED). The agency gran...

Global Team of Ophthalmologists Creates Questionnaire for Reporting Dysphotopsias
Global Team of Ophthalmologists Creates Questionnaire for Reporting Dysphotopsias

Twenty multinational ophthalmic specialists, including key opinion leaders, have developed a consensus-based classification system and questionnaire for reporting dysphotopsias after ophthalmic pro...

Bausch + Lomb Rolls Out Orphia Digital Platform, Initially Focused on Patient Education
Bausch + Lomb Rolls Out Orphia Digital Platform, Initially Focused on Patient Education

Bausch + Lomb reported July 9 the introduction of Orphia, a new AI-powered digital health platform intended to increase eye care providers’ efficiency. It will initially provide pre-surgery catarac...

Researchers Develop Dry Eye Candidate Powered by Spinach and Light
Researchers Develop Dry Eye Candidate Powered by Spinach and Light

Researchers in Singapore have developed a spinach-derived nanotechnology that enables corneal cells to produce a key antioxidant molecule when exposed to ambient light. The team at the National Uni...

HelpMeSee Accelerates MSICS Training in India with New Center in Guwahati
HelpMeSee Accelerates MSICS Training in India with New Center in Guwahati

Global nonprofit group HelpMeSee and its Indian subsidiary, HMS Vision Private Limited, have launched virtual training for manual small incision cataract surgery (MSICS) in Guwahati, India. Trainin...

New Marketplace Aims to Rescue Shelved Cell and Gene Therapies
New Marketplace Aims to Rescue Shelved Cell and Gene Therapies

Hundreds of cell and gene therapy (CGT) candidates have been shelved in recent years—not because they failed patients, but because they weren’t considered commercially viable. A new joint venture a...

MACs Propose Limiting Coverage for iDose TR
MACs Propose Limiting Coverage for iDose TR

Five Medicare administrative contractors (MACs) in the US are proposing to limit coverage for procedures implanting the Glaukos iDose TR in patients with glaucoma. The iDose TR is a drug-eluting in...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more